Galectin Therapeutics Inc (NASDAQ: GALT) kicked off on Monday, up 13.55% from the previous trading day, before settling in for the closing price of $2.51. Over the past 52 weeks, GALT has traded in a range of $0.73-$3.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -23.89%. While this was happening, its average annual earnings per share was recorded 11.84%. With a float of $43.42 million, this company’s outstanding shares have now reached $63.29 million.
The extent of productivity of a business whose workforce counts for 15 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Galectin Therapeutics Inc (GALT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Galectin Therapeutics Inc is 31.40%, while institutional ownership is 15.73%. The most recent insider transaction that took place on Dec 30 ’24, was worth 7,540. In this transaction Director of this company bought 6,500 shares at a rate of $1.16, taking the stock ownership to the 15,206 shares. Before that another transaction happened on Dec 23 ’24, when Company’s Chief Medical Officer sold 13,654 for $0.88, making the entire transaction worth $12,044. This insider now owns 26,346 shares in total.
Galectin Therapeutics Inc (GALT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 11.84% per share during the next fiscal year.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
Take a look at Galectin Therapeutics Inc’s (GALT) current performance indicators. Last quarter, stock had a quick ratio of 0.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
The latest stats from [Galectin Therapeutics Inc, GALT] show that its last 5-days average volume of 0.37 million was inferior to 0.44 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 81.69%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 62.15%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.72, while its 200-day Moving Average is $1.82. Now, the first resistance to watch is $2.96. This is followed by the second major resistance level at $3.08. The third major resistance level sits at $3.30. If the price goes on to break the first support level at $2.62, it is likely to go to the next support level at $2.40. The third support level lies at $2.28 if the price breaches the second support level.
Galectin Therapeutics Inc (NASDAQ: GALT) Key Stats
The company with the Market Capitalisation of 180.38 million has total of 63,292K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -47,050 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -9,630 K.
